Full-Time

Senior Manager

Bioanalysis

Posted on 10/6/2025

Kyowa Kirin

Kyowa Kirin

1,001-5,000 employees

Global specialty pharma leveraging fermentation and antibodies

Compensation Overview

$155k - $170k/yr

Princeton, NJ, USA

Hybrid

Hybrid position requiring some in-office presence.

Category
Biology & Biotech (2)
,
Requirements
  • Bachelor’s degree in life sciences, healthcare, or closely related discipline is required.
  • An advanced degree (MS or PhD) is highly desirable.
  • Minimum of five (5) years of pharmaceutical industry experience (Sponsor and/or CRO) in the bioanalysis of large and small molecule therapeutics.
  • Three (3) or more years of hands-on experience at a bioanalytical CRO or in conducting vendor oversight to support clinical development programs across all phases; experience with early-phase programs is strongly preferred.
  • Proven experience in preparing strategic regulatory communications and developing reports and summary documents for regulatory submissions.
  • Demonstrated ability to manage expedited sample analysis timelines while ensuring high-quality data delivery.
  • Experience in authoring and reviewing Work Instructions, Manuals, and/or Standard Operating Procedures (SOPs).
  • Strong familiarity with bioanalytical assay methodology including ligand-binding and cell-based assays, LCMS/MS, and novel technologies.
  • Strong analytical skills to resolve technical issues.
  • Ability to effectively use tables, figures, and listings for data review (adequacy of bioanalysis) and cleaning (no missing samples).
  • Advanced knowledge of guidance documents issued by ICH and local regulatory agencies such as FDA, EMA, PMDA, Health Canada.
  • Familiarity with critical reagents lifecycle management.
  • Basic proficiency in MS Office Suite.
Responsibilities
  • Managing PK and immunogenicity bioanalysis conducted at CROs including on-site CRO visits and assay troubleshooting with support from internal SMEs.
  • Providing bioanalytical guidance on PK and immunogenicity required for clinical projects to cross-functional global clinical study teams, including advising on bioanalytical sample collection and processing, and storage, and data transfer procedures.
  • Reviewing clinical study protocols and providing bioanalytical summaries and reports for clinical pharmacology reports and CSRs.
  • Developing summary documents for regulatory submission and participating in strategic communication with regulatory agencies.
  • Extensive collaboration with counterparts in Japan on activities/initiatives for bioanalytical method development/transfer, CRO qualification/ selection/visits, and process improvements, including creation of work instructions (WIs) and Standard Operation Procedures (SOPs) and co-leading task forces.
  • Ensuring full compliance with current global and local bioanalytical guidance and GxPs.
  • Simultaneously completing tasks on multiple projects including method validation and sample analysis activities, with support from internal team members.
Desired Qualifications
  • Experience with early-phase programs is strongly preferred.

Kyowa Kirin is a global specialty pharmaceutical company that develops medicines using fermentation and antibody technologies. Its products target areas like nephrology, oncology, and immunology, with therapies built from biologics and other drug modalities. The company emerged from a merger between Kyowa Hakko Kogyo and Kirin Pharma, combining Kyowa’s fermentation and microbiology expertise with Kirin’s pharma resources to create a worldwide focus on specialty drugs. Unlike broader drug companies, Kyowa Kirin concentrates on a defined set of indications and runs a research-and-development-led business that aims to deliver innovative treatments for patients in need.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1885

Simplify Jobs

Simplify's Take

What believers are saying

  • Libmeldy commercialization in MLD expands rare disease revenue streams globally.
  • Orchard pipeline programs in MPS, FTD, Crohn's disease address high unmet needs.
  • North Carolina manufacturing capacity supports cell and gene therapy market growth.

What critics are saying

  • Libmeldy reimbursement denial in UK, Germany, US collapses primary revenue driver.
  • Orchard pipeline failures in Phase 2/3 trials eliminate $478M acquisition rationale.
  • Gene therapy manufacturing delays at Sanford facility constrain supply and revenue ramp.

What makes Kyowa Kirin unique

  • 75+ years fermentation expertise underpins proprietary antibody and gene therapy platforms.
  • Orchard Therapeutics acquisition adds Libmeldy gene therapy for rare genetic diseases.
  • $530M Sanford biologics facility enables scaled manufacturing of advanced cell therapies.

Help us improve and share your feedback! Did you find this helpful?

Benefits

401(k) Company Match

Paid Vacation

Paid Sick Leave

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Hybrid Work Options

Pet Insurance

Tuition Assistance

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

-1%

2 year growth

-1%
Benzinga
Dec 15th, 2025
Link Cell Therapies raises $92M to advance CAR-T cancer treatments for solid and liquid tumors

Link Cell Therapies has emerged from stealth with $60 million in Series A funding led by Johnson & Johnson Innovation – JJDC, bringing total capital raised to $92 million. The South San Francisco–based oncology company is developing CAR-T therapies for solid and liquid tumours using proprietary logic-gating technology. The platform enables safe targeting of multiple antigens co-expressed on cancer cells whilst sparing healthy tissue. Co-founded by Dr Robbie Majzner and Dr Crystal Mackall at Stanford University in 2022, Link's lead programme, LNK001 for renal cell carcinoma, is on track for an IND application and Phase I trial in 2026. The Series A round included participation from founding investors Samsara BioCapital and Sheatree Capital, alongside new backers Bristol Myers Squibb, Kyowa Kirin and Wing Venture Capital.

FinSMEs
Mar 4th, 2025
Garuda Therapeutics Closes $50M Series A-1 Financing

Garuda Therapeutics, a Cambridge, MA-based hematopoietic stem cell (HSC) therapies company, raised $50M in Series A-1 funding

Cimeio Therapeutics
Dec 10th, 2024
Cimeio Therapeutics Announces Partnership with Kyowa Kirin to Develop Novel Cell Therapies

The partnership combines Cimeio's proprietary Shielded Cell and Immunotherapy (SCIP) platform with Kyowa Kirin's expertise in cellular therapies and underscores both companies' commitment to using emerging cell and gene therapy technologies to develop new ways to treat patients.

Business North Carolina
Nov 27th, 2024
Op/ed: Biotech's role in North Carolina's job-creation success

Kyowa Kirin, a Japanese global specialty pharmaceutical company, plans to invest more than $200 million in Sanford to build its first pharmaceutical manufacturing complex in North America, adding more than 100 new jobs.

World Pharmaceutical Frontiers
Jun 11th, 2024
Kyowa Kirin to establish new $530m biologics manufacturing plant in US

Japan-based Kyowa Kirin has unveiled its plans to invest $530m to build a new advanced biologics manufacturing facility in Sanford in the American state of North Carolina.

INACTIVE